enables to look at the distribution of reads alongside the relevant chromosome. Cut-off ≥ 15% of EWMA curve above upper limit was considered a high risk for trisomy. In case of positive cfDNA test, amniocentesis was performed to confirm the diagnosis. Results: A total of 4404 prenatal samples was processed since the start in January 2015. 4182 samples had test results evaluable and 222 samples (5.0 %) were re-sampled and re-processed. Out of 119 trisomic cases there was one false negative result for Trisomy 21 and one for Trisomy 18. Seven samples were false positives for Trisomy 13, ten samples for Trisomy 18 and 31 samples for Trisomy 21. The cfDNA test had a detection rate of 100 % for Trisomy 13 (n=9), 95.5 % for Trisomy 18 (n=22) and 98.9 % for Trisomy 21 (n=88). The false positive rates were 0.2 %, 0.2 % and 0.8 % for Trisomy 13, 18 and 21, respectively. The overall detection rate for all trisomies was 98.3 % and the overall false positivity was 1.2 %. Conclusions: We presented that cfDNA test can be successfully incorporated into fetal aneuploidy screening on a non-commercial basis. Our cfDNA test showed high sensitivity and low false positivity.
OC02.05
The influence of body mass index on fetal fraction increase and test failure rate in prenatal cell-free DNA testing Objectives: To assess the influence of body mass index (BMI) on fetal fraction increase with gestation and on no-call results and test failure. Methods: Cross-sectional study of consecutive singleton pregnancies where cell-free DNA (cfDNA) screening for fetal aneuploidies was performed from 10 weeks' gestation, between May 2013 and January 2018, at two fetal medicine clinics in Australia, using one of two platforms (A -Harmony ® Prenatal Test, Ariosa Diagnostics Inc; and B -nest TM , Verinata Health, Inc.). Maternal characteristics, fetal fraction, primary failures (''no-call'') and final test failures were recorded. BMI was classified as normal (< 25.0 kg/m 2 ), overweight (25.0 to 29.9 kg/m 2 ), obesity class I (30.0 -34.9 kg/m 2 ), and obesity classes II and III (≥ 35.0 kg/m 2 ). Fetal fraction and proportions of no-call results and test failure were compared, adjusted odds ratio with 95% CI and predicted probabilities were calculated for each BMI group using logistic regression. Results: Of 14,223 singleton pregnancies included, 8,583 (60.3%) were screened with platform A and 5,640 (39.7%) with platform B. Median fetal fraction values were lower and no-call and failure rates were higher in increased BMI groups (p<0.001). When compared to women with normal BMI, women with BMI ≥ 35 kg/m 2 had a significantly smaller increase in fetal fraction (0.1% vs 0.3% per week, p < 0.001). In this sub-group the odds ratios for a no-call result were 21.8 (95% CI 13.6-35.1) and 7.4 (95% CI 3.7-14.7) and for a failed result were 24.5 (95% CI 10.9-55.1) and 5.1 (95% CI 1.7-15.5), using platforms A and B respectively. Overall, the increase in fetal fraction was significantly larger after 20 weeks' gestation than before (1.1% per week vs 0.3% per week, p<0.001). Conclusions: There is only minimal fetal fraction increase between 10 and 20 weeks' gestation in women with BMI above 35 kg/m 2 . Postponing the test is unlikely to reduce test failure rates in this population.
OC02.06
Haplotype-based non-invasive prenatal testing for Duchenne muscular dystrophy: a pilot study in south China Objectives: To explore the accuracy and feasibility of a haplotype-based non-invasive prenatal testing (NIPT) for Duchenne Muscular Dystrophy (DMD). Methods: Singleton pregnancies at 12-25 weeks of gestation from seventeen families, each with a proband affected by DMD were recruited in the antenatal clinic.
The causative mutations in probands and their mothers were previously identified by multiplex ligation-dependent probe amplification (MLPA). Captured sequencing was performed on genomic DNA from parents and proband using customised hybridisation probes targeted at highly heterozygous 2358 SNPs located within the 1M region flanking DMD gene and its coding region to acquire parental haplotypes and the linkage to pathogenic mutations. Maternal plasma DNA obtained at 12-25 weeks of gestation also underwent targeted sequencing to deduce fetal haplotypes assisted by parental haplotypes. The fetal genotypes in DMD gene were further validated by invasive procedures of prenatal diagnosis. Results: The haplotype-based NIPT was successfully performed in all families. Four female and six male fetuses were identified to be normal. Four female fetuses were carriers and three male fetuses were DMD patients due to exons 49-52 deletion, exons 8-37 deletion and c.628G>T, respectively. All these results were consistent with those of invasive procedures. Conclusions: Haplotype-based non-invasive prenatal testing for DMD using targeted sequencing is promising and has potential for clinical implementation.
